Literature DB >> 12517278

Pharmacogenomics and reducing the frequency of adverse drug events.

Dennis J O'Kane, Richard M Weinshilboum, Thomas P Moyer.   

Abstract

Mesh:

Year:  2003        PMID: 12517278     DOI: 10.1517/phgs.4.1.1.22588

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  5 in total

1.  Integrating pharmacokinetics knowledge into a drug ontology: as an extension to support pharmacogenomics.

Authors:  C G Chute; J S Carter; M S Tuttle; M Haber; S H Brown
Journal:  AMIA Annu Symp Proc       Date:  2003

2.  Role of regulatory agencies in translating pharmacogenetics to the clinics.

Authors:  Krishna Prasad
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 3.  Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping.

Authors:  Ioannis S Vizirianakis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Membrane transporter proteins: a challenge for CNS drug development.

Authors:  François Girardin
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

5.  Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital.

Authors:  Pritmohinder S Gill; Feliciano B Yu; Patricia A Porter-Gill; Bobby L Boyanton; Judy C Allen; Jason E Farrar; Aravindhan Veerapandiyan; Parthak Prodhan; Kevin J Bielamowicz; Elizabeth Sellars; Andrew Burrow; Joshua L Kennedy; Jeffery L Clothier; David L Becton; Don Rule; G Bradley Schaefer
Journal:  J Pers Med       Date:  2021-05-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.